DOCSLIB.ORG

Metastatic Sarcoma to Review and Correlate 70 (Rhabdomyosarcoma 40%, with Previous Paraspinal Malignant Rhabdoid Tumor Pathology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ref code case diagnosis comment score 2289 448 AP221 Lung - metastatic sarcoma To review and correlate 70 (rhabdomyosarcoma 40%, with previous paraspinal malignant rhabdoid tumor pathology. To apply 40%, anaplastic Wilm's immunostaining to assist in tumour 20%) tumour classification. 2290 222 AP221 pleuropulmonary blastoma nil 50 2299 246 AP221 Metastatic malignant Panel of IHC stains: muscle 80 neoplasm; DDx rhabdoid specific actin, desmin, tumour (50%), myoD1, cytokeratin, EMA, rhabdomyosarcoma (50%) S100. EM: tangled intermediate filaments (in rhabdoid tumour) 2307 873 AP221 Malignant tumour, favour nil 50 rhabdomyosarcoma. Perform staining for desmin, myoD1 and actin (100% probability) 2324 663 AP221 Lung mass, excision - nil 50 Malignant tumor, favour metastatic sarcoma. Differential diagnosis includes metastatic poorly differentiated sarcoma, clear cell sarcoma of kidney and paraganglioma. 2332 911 AP221 Malignant biphasic tumour. Immunohistochemical stain 50 Metastatic nephroblastoma for EMA, Cam5.2, CD99 (50%). Poorly differentiated and bcl-2. synovial sarcoma (50%). RT-PCR for SYT-SSX translocation. 2340 109 AP221 Malignant tumour (100%) Malignant tumour, likely 50 metastatsis, has to correlate with previous tumour site and morphology for definitive diagnosis. Differential diagnoses include Wilm's tumour, synovial sarcoma, need to exclude germ cell tumour such as yolk sac tumour. 2350 369 AP221 Malignant neoplasm. DDx Do neuron specific enolase, 60 among neuroblastoma, synaptophysin, rhabdoid tumor( including chromogranin, atypical teratoid/rhabdoid neurofilament and NB84 tumor), which will be positive in rhabdomyosarcoma, and neuroblastoma. Wilm's tumor. Do EMA, vimentin and smooth muscle actin which will be mostly positive in ATRT. Also negative stain for INI1. Do myogenin which will be positive for rhabdomyosarcoma. Do WT1 which will be positive in Wilm's tumor. 2352 369 AP221 Forget to add the Nil. 0 probability of 100% in the previous submitted answer. 2353 517 AP221 METASTATIC SUGGEST 50 MALIGNANT TUMOUR IMMUNOHISTOCHEMICAL 100% STUDY IE MYOGENIN, DDX MYOD1, DESMIN, S100 RHABDOMYOSARCOMA, PROTEIN PERIPHERAL NERVE SHEATH TUMOUR 2362 338 AP221 Malignant tumor consistent Do immunostains eg. 50 with metastases. Favor a Myo-D1, desmin, AFP, sarcoma as primary. 100%. S100 etc The differential includes 1)Rhabdomyosarcoma 2)Leiomyosarcoma 3)Germ cell tumor 4)Neuroblastoma 5)Melanoma. 2370 763 AP221 High grade malignant tumor There are areas of 60 (likely metastatic) apparent biphasic epithelioid-spindle cell pattern and some rhabdoid cytomorphology. Differential diagnoses include synovial sarcoma, rhabdoid tumor, pleuropulmonary blastoma and primitive neuroectodermal tumor etc. Suggest correlation with histology, immunohistochemistry, molecular studies and radiological findings of the lung and paraspinal masses. 2378 333 AP221 Metastatic malignant Review previous paraspinal 100 spindle cell tumor (100%), tumor; differential diagnoses are Immunostaining : myoid rhabdomyosarcoma (10%), markers (myogenin, rhabdoid tumor(80%), desmin, actin) for PNET(3%), malignant rhabdomyosarcoma; peripheral nerve sheath cytokeratins for rhabdoid tumor(4%), neuroblastoma tumor, loss of INI1 in (3%). rhabdoid tumor, CD99 for PNET, S100, neuronal markers for neurogenic tumor. 2386 530 AP221 Metastatic sarcomatous Immunohistochemistry to 50 lesion. Differential differentiate especially diagnosis: - myogenin, desmin, EMA, Rhabdomyosarcoma; - ect. Synovial sarcoma. 2394 888 AP221 High-grade sarcoma, 1. Perform immunostains 50 differential diagnoses for differentiation: Synovial 1. Metastatic synovial sarcoma positive for EMA, sarcoma (50%) bcl-2, CD99; MPNST 2. Metastatic malignant positive for S100, Wilm peripheral nerve sheath tumour positive for WT1 tumour with glandular and PNET positive for differentiation (30%) chromogranin and 3. Metastatic Wilm synaptophysin. tumour (10%) 2. Retrieve old slides for 4. Metastatic Ewing assessment. tumour/PNET (10%) 2403 515 AP221 Metastatic malignant nil 50 tumour DDx: Wilm's tumour & rhabdomyosarcoma 2282 448 AP222 Endometrium - Complex Need follow up 50 hyperplasia with papillary aspirate/curettage or syncytial change and examination of uterus eosinophilic metaplasia specimen (if hysterectomy 100% done for other reason) to rule out malignancy. 2291 222 AP222 complex hyperplasia with nil 50 papillary syncytial metaplasia 2300 246 AP222 Endometrioid nil 100 adenocarcinoma, Grade 1, with focal microglandular pattern (100%) 2308 873 AP222 Mixed endometrioid and nil 90 serous adenocarcinoma (100% probability) 2315 369 AP222 Endometrioid This aspirate shows FIGO 100 adenocarcinoma.(100%) grade I. 2325 663 AP222 Endometrium - nil 100 Endometrioid adenocarcinoma, secretory variant 2333 911 AP222 Endometrioid nil 100 adenocarcinoma (100%). 2341 109 AP222 Atypical complex nil 80 hyperplasia with papillary syncytial metaplasia (100%) 2355 517 AP222 ENDOMETRIOID nil 100 CARCINOMA 100% 2363 338 AP222 Endometrioid nil 100 adenocarcinoma with florid microglandular pattern FIGO grade 1, in a background of atypical hyperplasia. 100% 2371 763 AP222 At least atypical complex Suggest more sampling to 80 hyperplasia and papillary exclude endometrial syncytial metaplasia carcinoma 2379 333 AP222 Endometrioid This tumor biopsy exhibits 100 adenocarcinoma features of microglandular hyperplasia-like change, and eosinophilic metaplasia. 2387 530 AP222 Complex atypical nil 80 hyperplasia with papillary syncytial metaplasia, focally bordering on Adenocarcinoma. 2395 888 AP222 Endometrioid nil 100 adenocarcinoma (100%) 2404 515 AP222 Endometrioid nil 100 adenocarcinoma, low grade. 2283 448 AP223 Kidney - composite nil 100 Papillary carcinoma and Tubulocystic carcinoma 100% 2292 222 AP223 papillary renal cell nil 90 carcinoma 2301 246 AP223 Renal cell carcinoma, If there is clinical history of 90 mixed pattern (conventional end stage renal failure, the & papillary) (100%) diagnosis would be acquired cystic disease associated Renal cell carcinoma 2309 873 AP223 Multilocular cystic renal cell nil 80 carcinoma (100% probability) 2316 369 AP223 Renal cell nil 80 carcinoma.(100%) 2326 663 AP223 Kidney - Renal cell The overall features are 80 carcinoma, grade 2 suggestive of renal cell (Fuhrman) carcinoma complicating acquired cystic disease secondary to chronic dialysis. The prognosis is better than sporadic cases. 2334 911 AP223 Tubulocytic carcinoma Immunohistochemical stain 95 (100%). for CK7. 2342 109 AP223 Papillary renal cell nil 90 carcinoma (100%) 2356 517 AP223 PAPILLARY RENAL CELL nil 90 CARCINOMA TYPE II NUCLEAR GRADE 2 100% 2364 338 AP223 Tubulocystic carcinoma nil 100 with a component of papillary renal cell carcinoma, Furhman nuclear grade 3 out of 4. 100% 2372 763 AP223 Renal cell carcinoma There are focal cystic and 90 papillary areas. Suggest correlation with clinical history for evidence of acquired cystic disease of kidney and history of renal dialysis. 2380 333 AP223 Papillary renal cell Correlate with clinical 90 carcinoma (associated with finding of presence of acquired renal cystic end-stage renal disease. disease) 2388 530 AP223 Renal cell carcinoma, nil 90 papillary variant. 2396 888 AP223 Papillary renal cell nil 90 carcinoma (100%) 2402 515 AP223 Papillary renal cell nil 90 carcinoma 2288 448 AP224 Submandibular mass - To be differentiated by 100 Solitary fibrous tumour 90% immunostaining. SFT is - Myofibroma 10% actin-ve. 2293 222 AP224 solitary fibrous tumor nil 100 2302 246 AP224 Haemangiopericytoma IHC stain: CD34 (expected 80 (100%) to be positive) 2310 873 AP224 Vasoformative tumour DDx: nil 80 hemangiopericytoma, haemangioendothelioma, solitary fibrous tumour, cellular hemangioma (100% probability) 2327 663 AP224 Submandibular mass - The diagnosis can be 100 Solitary fibrous tumour. confirmed by immunostaining for CD34. Also rule out vascular tumour and smooth muscle tumour by CD31, smooth muscle actin and desmin. 2335 911 AP224 Solitary fibrous tumour Immunohistochemical stain 100 (100%). for CD34 and CD99. 2343 109 AP224 Solitary fibrous tumour Confirm with immunostain 100 (100%) for CD34. 2354 369 AP224 Vascular neoplasm, favors Do CD31 to confirm 40 capillary hemangioma. DDx vascular channels. includes Do smooth muscle actin to hemangioendothelioma and exclude glomus type tumor. glomus type tumor.(100%) 2357 517 AP224 SOLITARY FIBROUS nil 100 TUMOUR 100% 2365 338 AP224 Solitary fibrous tumor To confirm by CD34 stain. 100 100%. 2373 763 AP224 Benign spindle cell tumor: nil 80 differential diagnoses include myofibroma and solitary fibrous tumor, to be differentiated by CD34 and actin immunostaining 2385 333 AP224 Solitary fibrous tumor Immnostaining for CD34 for 100 (80%) solitary fibrous tumor; actin Cellular capillary to highlight lobulation and hemangioma (20%) pericytes in capillary hemangioma. 2389 530 AP224 Spindle cell tumor. nil 80 Differential diagnosis: Myoepithelioma, Solitary fibrous tumor, Hemangiopericytoma. 2397 888 AP224 Differential diagnosese: Perform immunostains for 60 1. Epithelioid differentiation: Epithelioid haemangioendothelioma haemangioendothelioma (70%) positive for factor VIII, 2. Solitary fibrous tumour CD31 and CD34; SFT (30%) positive for CD34 only. 2405 515 AP224 Solitary fibrous tumour nil 100 2284 448 AP225 Ovary - Brenner tumour nil 100 100% 2294 222 AP225 benign brenner tumor nil 100 2295 222 AP225 benign Brenner tumor nil 100 2303 246 AP225 Benign Brenner tumour nil 100 (100%) 2311 873 AP225 Benign Brenner tumour nil 100 (100% probability) 2317 369
Recommended publications
  • Rare Case Botryoid Rhabdomyosarcomas of the Genital Tract

    Rare Case Botryoid Rhabdomyosarcomas of the Genital Tract

    ISSN: 2581-5407 DOI: https://dx.doi.org/10.17352/gjct CLINICAL GROUP Received: 25 April, 2020 Case Report Accepted: 29 April, 2020 Published: 30 April, 2020 *Corresponding author: M Lahfaoui, Department Rare Case Botryoid of Pediatric Visceral and Urogenital Surgery, Oujda Children’s Hospital. Morocco, E-mail: Rhabdomyosarcomas of the https://www.peertechz.com Genital Tract. About a case in a 30-month-old child M Lahfaoui* and H Benhaddou Department of Pediatric Visceral and Urogenital Surgery, Oujda Children’s Hospital. Morocco Abstract Rhabdomyosarcomas are the most common soft tissue sarcomas developed in children under 15 years of age. The reported fi nding is a vaginal tumour developed in a 30-month-old granddaughter. This was a typical botryoid rhabdomyosarcoma that usually occurs in the hollow organs lined with mucous membrane. Rhabdomyosarcomas have multiple aspects that vary according to the degree of cellular differentiation. The majority of these tumours can be classifi ed into four histological categories: embryonic, botryoid, alveolar or pleomorphic. Treatment involves excisional surgery combined with radiotherapy and chemotherapy. The prognosis remains bleak despite therapeutic advances in recent years. Introduction Anatomopathological examination of the specimen showed that it was a polypoid (grape-like) tissue bordered Rhabdomyosarcomas are the most common soft tissue by a slightly hyperplastic squamous epithelium. Beneath sarcomas developed in children under 15 years of age. this epithelium, within a myxoid layer, a proliferation of These tumours respond to multidisciplinary management: disseminated tumour cells was observed with an inconspicuous conservative surgery (Figure1), multi-chemotherapy and cytoplasm, a hyperchromatic, rounded or elongated nucleus, radiotherapy. Although the prognosis is always dire, a sometimes presenting cytonuclear atypia with monstrosity signifi cant proportion of children treated in this way do not metastasize [1].
  • Histological Tumour Type (Required)

    Histological Tumour Type (Required)

    Histological tumour type (Required) Reason/Evidentiary Support All ovarian epithelial malignancies and borderline tumours should be typed according to the WHO classification.1 There are 5 major subtypes of primary ovarian carcinoma, high‐grade serous, clear cell, endometrioid, mucinous and low‐ grade serous.2‐5 There are also other uncommon minor subtypes, those listed by the WHO including malignant Brenner tumour, seromucinous carcinoma and undifferentiated carcinoma.1 Carcinosarcoma is a mixed epithelial and mesenchymal malignancy but is included in the category of epithelial malignancies in this dataset since most are of epithelial origin and histogenesis.6 Although management of ovarian carcinoma is, at present, largely dependent on tumour stage and grade, accurate typing will almost certainly become more important in the future with the introduction of targeted therapies and specific treatments for different tumour types. This is in part because, although clinically often considered as one disease, there is an increasing realisation that the different morphological subtypes of ovarian carcinoma have a different pathogenesis, are associated with distinct molecular alterations and have a different natural history, response to traditional chemotherapy and prognosis.2‐5 Tumour typing may also be important in identifying or initiating testing for an underlying genetic predisposition; for example, high‐grade serous carcinoma may be associated with underlying BRCA1/2 mutation while endometrioid and clear cell carcinomas can occur in patients with Lynch syndrome.7 The most common ovarian carcinoma is high‐grade serous carcinoma (approximately 70%) followed by clear cell and endometrioid.8,9 Mucinous and low‐grade serous are less common. Approximately 90% of advanced stage ovarian carcinomas (stage III/IV) are high‐grade serous in type.8,9 Most primary tubal carcinomas are high‐grade serous or endometrioid and most primary peritoneal carcinomas are of high‐grade serous type.
  • Soft Tissue Sarcoma Classifications

    Soft Tissue Sarcoma Classifications

    Soft Tissue Sarcoma Classifications Contents: 1. Introduction 2. Summary of SSCRG’s decisions 3. Issue by issue summary of discussions A: List of codes to be included as Soft Tissue Sarcomas B: Full list of codes discussed with decisions C: Sarcomas of neither bone nor soft tissue D: Classifications by other organisations 1. Introduction We live in an age when it is increasingly important to have ‘key facts’ and ‘headline messages’. The national registry for bone and soft tissue sarcoma want to be able to produce high level factsheets for the general public with statements such as ‘There are 2000 soft tissue sarcomas annually in England’ or ‘Survival for soft tissue sarcomas is (eg) 75%’ It is not possible to write factsheets and data briefings like this, without a shared understanding from the SSCRG about which sarcomas we wish to include in our headline statistics. The registry accepts that soft tissue sarcomas are a very complex and heterogeneous group of cancers which do not easily reduce to headline figures. We will still strive to collect all data from cancer registries about anything that is ‘like a sarcoma’. We will also produce focussed data briefings on sites such as dermatofibrosarcomas and Kaposi’s sarcomas – the aim is not to forget any sites we exclude! The majority of soft tissue sarcomas have proved fairly uncontroversial in discussions with individual members of the SSCRG, but there were 7 particular issues it was necessary to make a group decision on. This paper records the decisions made and the rationale behind these decisions. 2. Summary of SSCRG’s decisions: Include all tumours with morphology codes as listed in Appendix A for any cancer site except C40 and C41 (bone).
  • Cellular Pseudosarcomatous Fibroepithelial Stromal Polyp of the Cervix: a Lesion Mimicking As Sarcoma

    Cellular Pseudosarcomatous Fibroepithelial Stromal Polyp of the Cervix: a Lesion Mimicking As Sarcoma

    Advances in Cytology & Pathology Case Report Open Access Cellular pseudosarcomatous fibroepithelial stromal polyp of the cervix: a lesion mimicking as sarcoma Abstract Volume 3 Issue 1 - 2018 Introduction: Fibroepithelial stromal polyps (FESP) are infrequent mesenchymal Mahboob Hasan1 ,Ruquiya Afrose2 ,Mariya lesions found in vulvovaginal region but may also occur in the cervix, usually 1 seen in reproductive age group. FESP exhibiting bizarre cytomorphology, atypical Kamal 1Department of pathology, Aligarh Muslim University, India mitoses, or hypercellularity, raises the possibility of malignancy and continue to be 2Department of pathology, Uttar Pradesh University of Medical underrecognized. Sciences, India Case summary: We report a case of 45 years old, postmenopausal female presented with a large polypoidal cauliflower like growth with ulcerated surface, arising from Correspondence: Ruquiya Afrose, Assistant professor, Department of Pathology, Uttar Pradesh University of Medical exocervix. Cinical diagnosis of cervical malignancy was suggested. Histopathological Sciences, Saifai Etawah, 206301, India, Tel 9219716166, examination revealed a polypoidal tumor mass composed of cellular fibrovascular Email [email protected] stroma covered with stratified squamous epithelium. There are areas showing marked hypercellularity, bizarre cytomorphology and frequent mitotic figures (>10/10 HPF) Received: November 17, 2016 | Published: February 21, 2018 including atypical ones. Important morphologic clues to the diagnosis of FESP were its superficial
  • BSOG-FOGSI Quiz Preliminary Round Conducted on 24Th April at API

    BSOG-FOGSI Quiz Preliminary Round Conducted on 24Th April at API

    BSOG-FOGSI quiz preliminary round conducted on 24th April at API Bhavana South Zone Yuva Fogsi 2016 Quiz – BSOG round Topic- Gynecological Oncology 24th April, 2016 (60 marks) Name: Institution: Dear participants, Welcome to the FOGSI Quiz 2016 Thirty questions are to be answered in 30 minutes. Circle the right answer. Scratching and overwriting will get a negative marking even if the final answer is right. Each correct answer gets 2 marks and a wrong one gets a negative marking of minus 1.The top 2 scorers will represent BSOG in South Zone Yuva FOGSI 2016 in Madurai on 22nd May 2016. The decision of the Quiz Master is final. Happy Quizzing!!! 1. With regards to the staging of endometrial cancer, pick the wrong answer a. Stage 1a Endometrial Adenocarcinoma is confined to the uterus and involves less than half of the myometrium b. Stage 4a Endometrial Adenocarcinoma invades bladder mucosa c. Stage 4b Endometrial Adenocarcinoma involves inguinal lymph nodes d. Stage 3c2 Endometrial Adenocarcinoma involves more than half of myometrium and pelvic lymph nodes Ans: Stage 3c1 is involvement of pelvic nodes, Stage 3c2 is involvement of paraaortic nodes 2. The average time between HPV infection and pre-cancer is a. 2-5 years b. 15-20 years c. 7-10 years d. 20-25 years Novak 3. What factor does not contribute to persistence and progression of HPV infection? a. Smoking b. Contraceptive use c. STDs d. Drinking alcohol Novak 4. On Colposcopy, Adenocarcinoma has the following features a. Mosaic pattern b. Punctate lesions c. Abnormal vasculature d.
  • Sarcoma of the Vagina

    Sarcoma of the Vagina

    570 MCFARLAND: SARCOMA OF VAGINA Thompson and Harris. Jour. Med. Research, 190S, xiv. 135. Thompson. CtbU. f. allg. Path. u. path. Anat., l'JO'J, xx, 91G. Vassalo and Generali. Rivista di patol. Xerv. o Ment., IStHJ, i. 95; Arch. ital. de biol., 189G, xxv. 459; ibid., xxvi, Gl. Vassale. Arch. ital. de biol., 1S9S, xxx, 49. Von VerebOy, Virchow's Archive 1907, clxxxvii. SO. Wasscrtrilling. Alls. Wiener rued. Ztg., 190S. liii. 2S9. 299, 312. Weiss. Ueber Tetanic, Volkmann’s S:numlui)K klin. Vortrage, 1SS1, Nr. 1S9, 1G75. Welsh. Jour. Anat. and Physiol., 1S9S, xxxii, 292 and 3S0. Yanasc. Jalirb. fur Kinderheilkunde. Ixvii, Frsanxunsshcft, 190S, 57. SARCOMA OF THE VAGINA. A STATISTICAL STUDY OF 102 CASES, WITH THE REPORT OF A NEW CASE OF THE GRAPE-LIKE SARCOMA OF THE VAGINA IN AN INFANT. By Joseph McFarland, M.D., ruornssnn or tathologt and r.ACTxniou>cr i.v Tin; ucDtco-cinnunniCAX, coixrcr, nilLADCLFUlA. Sarcoma of the vagina is so rare an affection that the literature contains a total of 101 eases to which I add a new one, making 102 cases upon record. Its rarity and its fatality combine to make it an interesting affection, and when an attempt is made to review the literature of the subject so many features of interest present themselves that the matter becomes quite absorbing. Sarcoma of the female organs of generation may be divided clin¬ ically into those arising from the vulva, from the vagina, from the vesicovagii d septum, from the rectovaginal septum, from the cervix uteri, trout the corpus uteri, and from the ovary.
  • Primary Endometrial Stromal Sarcoma Arising from Cervix

    Primary Endometrial Stromal Sarcoma Arising from Cervix

    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 12 Ver. VI (Dec. 2015), PP 139-144 www.iosrjournals.org Primary Endometrial Stromal Sarcoma arising from Cervix Dr. Jindal Dweep1, Dr. Jindal Manjusha2 1(Ex Senior resident, Department of OBG, Goa Medical College, Bambolim, Goa, India) 2(Associate professor, Department of OBG, Goa Medical College, Bambolim, Goa, India) Abstract:Endometrial stromal sarcomas are rare malignant tumors of the uterus (0.2% of all uterine malignancies). The primary tumor can occur in extra-uterine sites like ovary, fallopian tube, cervix, vulva, vagina, omentum and retro peritoneum. There are only 18 cases reported in literature of ESS arising from cervix till date. Primary tumor arising in the cervix mimics a fibroid polyp and poses a diagnostic dilemma. A pre-operative diagnosis of ESS is difficult and the diagnosis is retrospective from histopathology of a hysterctomy specimen done for presumed benign disease. We report a case of 48 years old perimenopausal lady who presented with irregular bleeding per vaginum and retention of urine. Clinical examination was suggestive of degenerated fibroid polyp. She gave history of removal of similar mass nine months earlier, the details of which were not known. In view of her age and recurrence of symptoms, total hysterectomy with bilateral salpingo-oophrectomy was done. The diagnosis was established on gross findings, cut section, histopathology and immunohistochemistry. The case report emphasises the need to include ESS in the differential diagnosis of cervical polyp.The role of adjuvant hormone therapy, chemotherapy and radiation is discussed.
  • SNOMED CT Codes for Gynaecological Neoplasms

    SNOMED CT Codes for Gynaecological Neoplasms

    SNOMED CT codes for gynaecological neoplasms Authors: Brian Rous1 and Naveena Singh2 1Cambridge University Hospitals NHS Trust and 2Barts Health NHS Trusts Background (summarised from NHS Digital): • SNOMED CT is a structured clinical vocabulary for use in an electronic health record. It forms an integral part of the electronic care record, and serves to represent care information in a clear, consistent, and comprehensive manner. • The move to a single terminology, SNOMED CT, for the direct management of care of an individual, across all care settings in England, is recommended by the National Information Board (NIB), in “Personalised Health and Care 2020: A Framework for Action”. • SNOMED CT is owned, managed and licensed by SNOMED International. NHS Digital is the UK Member's National Release Centre for the creation of, and delegated authority to licence the SNOMED CT Edition and derivatives. • The benefits of using SNOMED CT in electronic care records are that it: • enables sharing of vital information consistently within and across health and care settings • allows comprehensive coverage and greater depth of details and content for all clinical specialities and professionals • includes diagnosis and procedures, symptoms, family history, allergies, assessment tools, observations, devices • supports clinical decision making • facilitates analysis to support clinical audit and research • reduces risk of misinterpretations of the record in different care settings • Implementation plans for England: • SNOMED CT must be implemented across primary care and deployed to GP practices in a phased approach from April 2018. • Secondary care, acute care, mental health, community systems, dentistry and other systems used in direct patient care must use SNOMED CT as the clinical terminology, before 1 April 2020.
  • Brenner Tumor with Serous Cystadenoma- an Unusual Combination: a Case Report

    Brenner Tumor with Serous Cystadenoma- an Unusual Combination: a Case Report

    DOI: 10.5958/2319-5886.2015.00045.4 International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 4 Issue 1 Coden: IJMRHS Copyright @2014 ISSN: 2319-5886 Received: 6th Nov 2014 Revised: 28th Nov 2014 Accepted: 31st Dec 2014 Case report BRENNER TUMOR WITH SEROUS CYSTADENOMA- AN UNUSUAL COMBINATION: A CASE REPORT *Syam Sundar B1, Shanthi V1, Mohan Rao N1, Bhavana Grandhi2, Chidananda Reddy V 2, Swathi S2 1Associate Professor, 2Assistant professor, Department of Pathology, Narayana Medical College, Nellore, A.P, India *Corresponding author email: syam.byna&gmail.com ABSTRACT Surface epithelial tumors are most common, which comprise 58% of all ovarian tumors. Serous and mucinous cystadenoma are the most common epithelial tumors which accounts for about 35% of ovarian tumors. Different combinations of epithelial tumors can occur in ovary most common among them is Mucinous cystadenoma and Brenner tumor. We report a case of an ovarian tumor with rare combination Brenner tumor with serous cyst adenoma of ovary in 56 year old female patient. Only a few cases with this combination are very rarely reported in the literature. Keywords: Brenner Tumor, Serous cystadenoma. INTRODUCTION Surface epithelial tumors are the most important CASE REPORT group of neoplasm of ovary which are namely serous, mucinous, endometroid, clear cell and Brenner along A 56 year old female patient presented with a with combinations of these types1. Surface epithelial swelling in the lower abdomen with intermittent tumors occur at all ages with a peak incidence in 2nd abdominal pain over a period of 1 year. Clinically, to 5th decade of life.
  • Rotana Alsaggaf, MS

    Rotana Alsaggaf, MS

    Neoplasms and Factors Associated with Their Development in Patients Diagnosed with Myotonic Dystrophy Type I Item Type dissertation Authors Alsaggaf, Rotana Publication Date 2018 Abstract Background. Recent epidemiological studies have provided evidence that myotonic dystrophy type I (DM1) patients are at excess risk of cancer, but inconsistencies in reported cancer sites exist. The risk of benign tumors and contributing factors to tu... Keywords Cancer; Tumors; Cataract; Comorbidity; Diabetes Mellitus; Myotonic Dystrophy; Neoplasms; Thyroid Diseases Download date 07/10/2021 07:06:48 Link to Item http://hdl.handle.net/10713/7926 Rotana Alsaggaf, M.S. Pre-doctoral Fellow - Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH PhD Candidate – Department of Epidemiology & Public Health, University of Maryland, Baltimore Contact Information Business Address 9609 Medical Center Drive, 6E530 Rockville, MD 20850 Business Phone 240-276-6402 Emails [email protected] [email protected] Education University of Maryland – Baltimore, Baltimore, MD Ongoing Ph.D. Epidemiology Expected graduation: May 2018 2015 M.S. Epidemiology & Preventive Medicine Concentration: Human Genetics 2014 GradCert. Research Ethics Colorado State University, Fort Collins, CO 2009 B.S. Biological Science Minor: Biomedical Sciences 2009 Cert. Biomedical Engineering Interdisciplinary studies program Professional Experience Research Experience 2016 – present Pre-doctoral Fellow National Cancer Institute, National Institutes
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019

    New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019

    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
  • Fibroepithelial Polyp of Vagina – a Rare Case Report Sujata Kumbhar1*, Digvijay Patil2, Shoaib Khoja3, Garima Agarawal3, Divya Brahmbhatt3, Vaidehi Nagar3

    Fibroepithelial Polyp of Vagina – a Rare Case Report Sujata Kumbhar1*, Digvijay Patil2, Shoaib Khoja3, Garima Agarawal3, Divya Brahmbhatt3, Vaidehi Nagar3

    Scholars Journal of Medical Case Reports Abbreviated Key Title: Sch J Med Case Rep ISSN 2347-9507 (Print) | ISSN 2347-6559 (Online) Journal homepage: https://saspublishers.com Fibroepithelial Polyp of Vagina – A Rare Case Report Sujata Kumbhar1*, Digvijay Patil2, Shoaib Khoja3, Garima Agarawal3, Divya Brahmbhatt3, Vaidehi Nagar3 1Professor, Department of Pathology, Krishna Institute of Medical Sciences, Deemed to be University, Karad, India 2Department of Obstetrics and Gynaecology, Krishna Institute of Medical Sciences, Deemed to be University, Karad, India 3Tutor, Department of Pathology, Krishna Institute of Medical Sciences, Deemed to be University, Karad, India DOI: 10.36347/sjmcr.2020.v08i11.012 | Received: 12.10.2020 | Accepted: 25.10.2020 | Published: 20.11.2020 *Corresponding author: Dr. Sujata Kumbhar Abstract Case Report Polypoid lesions or grape like masses of vagina are always worrisome and uncommon. In infants and young girls, such lesions are suspicious for sarcoma botryoides. In adults, benign vaginal polyps with bizarre stromal cells may occur, leading to a misdiagnosis of sarcoma. Fibroepithelial polyps of the vagina (FEPV) have attracted special interest during the past decades because of the presence of atypical cells and abnormal mitoses in some of them 2'. Fibroepithelial polyps of the vagina (FEPV) are mucosal polypoid lesions with a connective tissue core covered by a benign squamous epithelium. They are thought to be rare. Here we present an unusual case of 42 years old female patient with complaint of pain in lower abdomen since 6 months diagnosed with fibroepithelial polyp of the vagina (FEPV). Keywords: Polypoid lesions, botryoides, epithelium, fibroepithelial. Copyright © 2020 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.